Abstract
The goal of current cancer care is a risk-adjusted patient- specific treatment planned to maximize cancer control while minimizing the risk of complications [1]. In prostate cancer (PCa), accurate tumor characterization and disease staging are of great importance in choosing appropriate therapeutic management from a wide array of alternatives including deferred therapy (watchful waiting), androgen ablation, radical surgery and external radiation [2, 3].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Hricak H, Choyke PL, Eberhardt SC et al (2007) Imaging prostate cancer: a multidisciplinary perspective. Radiology 243:28–53
Langsteger W, Heinisch M, Fogelman I (2006) The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Seminars in Nuclear Medicine 36:73–92
Beheshti M, Imamovic L, Broinger G et al (2010) 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 254:925–933
Langsteger W, Haim S, Knauer M et al (2012) Imaging of bone metastases in prostate cancer: an update. QJ Nucl Med Mol Imaging 56:447–458
Kwee SA, Coel MN, Lim J, Ko JP (2005) Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol 173:252–255
Beauregard JM, Williams SG, Degrado TR (2010) Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer. J Med Imaging Radiat Oncol 54:325–332
Poulsen MH, Bouchelouche K, Gerke O et al (2010) [18F]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study. BJU Int 106:639–643
Beheshti M, Vali R, Waldenberger P et al (2009) The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol 11:446–454
Beheshti M, Vali R, Waldenberger P et al (2008). Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 35:1766–1774
Beheshti M, Haim S, Zakavi R et al (2013) Impact of 18F Choline PET/CT in prostate cancer patients with biochemical recurrence — influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med, in press
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Italia
About this chapter
Cite this chapter
Langsteger, W., Beheshti, M. (2013). Imaging of Metastatic Bone and Soft Tissue Lesions in Prostate Cancer with FCH PET/CT. In: Hodler, J., von Schulthess, G.K., Zollikofer, C.L. (eds) Musculoskeletal Diseases 2013–2016. Springer, Milano. https://doi.org/10.1007/978-88-470-5292-5_29
Download citation
DOI: https://doi.org/10.1007/978-88-470-5292-5_29
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-5291-8
Online ISBN: 978-88-470-5292-5
eBook Packages: MedicineMedicine (R0)